Older adults who had a negative history of depression ... The Patient-Reported Outcomes Measurement Information System (PROMIS) depression scale was used to determine the depression status.

Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder ... improvements for ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Depression in older adults, also called geriatric depression, is a mental and emotional disorder affecting older adults. Feelings of sadness and occasional “blue” moods are normal. However ...

A new study found that retirees who drank moderately had fewer depression symptoms than non-drinkers, but retirees who drank ...

The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment ... on the Montgomery-Asberg Depression Rating Scale, compared with 7.6 percent ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

According to the US Department of Health and Human Services, the depression prevalence rate for young adults, which ranges from 10% to 85 ... the Center for Epidemiological Studies Depression Scale ...